253
Views
16
CrossRef citations to date
0
Altmetric
Original Articles

Development of antibodies against the fluoroquinolone sarafloxacin and molecular modeling studies of cross‐reactive compounds

, &
Pages 13-26 | Received 22 Jul 1996, Accepted 31 Oct 1996, Published online: 16 Sep 2008
 

Abstract

Polyclonal antibodies were prepared against the fluoroquinolone sarafloxacin. Sarafloxacin was conjugated directly to cationized bovine serum albumin (BSA) and ovalbumin. Balb/c mice were immunized with the sarafloxacin‐BSA conjugate (cBSA‐saraflox) and sarafloxacin‐reactive sera (1–5) were obtained from these mice. Serum from mouse 1 (Abl) exhibited the lowest IC50 for free sarafloxacin using an indirect competitive inhibition ELISA (ci‐ELISA). Other structurally related quinolones, including difloxacin, enrofloxacin, norfloxacin, trovafloxacin and nalidixic acid, demonstrated cross‐reactivity with the sarafloxacin antibodies as determined by ci‐ELISA. In an effort to correlate antibody binding with three‐dimensional properties of the cross‐reactive compounds, all of the fluoroquinolones as well as nalidixic acid were modeled, and global energy minima were determined using molecular mechanical and quantum mechanical methods. The results demonstrate that the three‐dimensional models can yield information that explains observed cross‐reactivity data. These models are particularly helpful when the chemical structure of an analog varies greatly from the immunogen yet the IC50 value for the compound is not vastly different. Furthermore, conformational and electronic data from this study can be used to predict whether other fluoroquinolones will exhibit good cross‐reactivity in this ELISA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.